arGEN-X
ROTTERDAM, the Netherlands and GHENT, Belgium, December 1, 2011 -
Funds will be Used to Progress Differentiated Therapeutic Antibody Programs into Clinical Development
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announced today the closing of a EUR 27.5 million (USD 37 million) Series B fundraising round, which was oversubscribed.
ROTTERDAM, The Netherlands, September 7, 2011 -
SIMPLE Antibody™ platform continues to demonstrate clear advantagesin therapeutic antibody discovery
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody™ platform, will provide an update on this year's significant corporate progress during a presentation by its CEO Tim Van Hauwermeiren at the BioPharm America conference in Boston, MA, USA (www.ebdgroup.com/bpa/).
ROTTERDAM, the Netherlands, GHENT, Belgium, PRINCETON, New Jersey, July 26, 2011 -
Synergistic Effect of Applying Potelligentto Simple Antibodies™ Creates Best-in-class Antibody Therapeutics
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENTTechnology.
ROTTERDAM, The Netherlands, July 8, 2010 - arGEN-X, a biopharmaceutical company focused on the discovery
and development of human monoclonal antibodies using its proprietary SIMPLE
Antibody(TM) platform, announces that it has been granted the first patent
covering the platform.
ROTTERDAM, The Netherlands, March 1, 2010 -
- SIMPLE Antibody(TM) Platform Delivers Unprecedented Choice
of Ultra-Potent Functional Antibody Leads Against Challenging Soluble
and Cell Surface Targets.
